| Autor: |
Ankley, Gerald T.1 (AUTHOR) ankley.gerald@epa.gov, Berninger, Jason P.1 (AUTHOR), Maloney, Erin M.2 (AUTHOR), Olker, Jennifer H.1 (AUTHOR), Schaupp, Christopher M.3 (AUTHOR), Villeneuve, Daniel L.1 (AUTHOR), LaLone, Carlie A.1 (AUTHOR) |
| Předmět: |
|
| Zdroj: |
Environmental Toxicology & Chemistry. Mar2024, Vol. 43 Issue 3, p537-548. 12p. |
| Abstrakt: |
There are insufficient toxicity data to assess the ecological risks of many pharmaceuticals and personal care products (PPCPs). While data limitations are not uncommon for contaminants of environmental concern, PPCPs are somewhat unique in that an a priori understanding of their biological activities in conjunction with measurements of molecular, biochemical, or histological responses could provide a foundation for understanding mode(s) of action and predicting potential adverse apical effects. Over the past decade significant progress has been made in the development of new approach methodologies (NAMs) to efficiently quantify these types of endpoints using computational models and pathway‐based in vitro and in vivo assays. The availability of open‐access knowledgebases to curate biological response (including NAM) data and sophisticated bioinformatics tools to help interpret the information also has significantly increased. Finally, advances in the development and implementation of the adverse outcome pathway framework provide the critical conceptual underpinnings needed to translate NAM data into predictions of the ecologically relevant outcomes required by risk assessors and managers. The evolution and convergence of these various data streams, tools, and concepts provides the basis for a fundamental change in how ecological risks of PPCPs can be pragmatically assessed. Environ Toxicol Chem 2024;43:537–548. © 2022 SETAC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA. [ABSTRACT FROM AUTHOR] |
| Databáze: |
GreenFILE |
| Externí odkaz: |
|
Plný text